Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells

被引:0
|
作者
Yuna Youn
Jong-chan Lee
Jaihwan Kim
Jae Hyeong Kim
Jin-Hyeok Hwang
机构
[1] Seoul National University Bundang Hospital,Department of Internal Medicine
[2] Seoul National University College of Medicine,Department of Internal Medicine
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cell division cycle 6 (Cdc6) plays key roles in regulating DNA replication, and activation and maintenance of cell cycle check points. In addition, Cdc6 exerts oncogenic properties via genomic instability associated with incomplete DNA replication. This study aimed to examine the effects of Cdc6 on pancreatic cancer (PC) cells. Our results showed that Cdc6 expression was higher in clinical PC specimens (based on analysis of the GEPIA database) and cell lines, and the high Cdc6 expression was associated with poorer survival in The Cancer Genome Atlas-PC cohort. In addition, Cdc6-depleted PC cells significantly inhibited cell proliferation and colony formation, delayed G2/M cell cycle progression, and increased expression of p-histone H3 and cyclin A2 levels. These observations could be explained by Cdc6 depletion leading to multipolar and split spindles via centrosome amplification and microtubule disorganization which eventually increases chromosome missegregation. Furthermore, Cdc6-depleted PC cells showed significantly increased apoptosis, which was consistent with increased caspase-9 and caspase-3 activation. Collectively, our results demonstrated that Cdc6-depleted PC cells are arrested in mitosis and eventually undergo cell death by induced multipolar spindles, centrosome aberrations, microtubule disorganization, and chromosome instability. In conclusion, Cdc6 may be a potential biomarker and therapeutic target for PC.
引用
收藏
相关论文
共 50 条
  • [31] Downregulation of Cdc6 and pre-replication complexes in response to methionine stress in breast cancer cells
    Booher, Keith
    Lin, Da-Wei
    Borrego, Stacey L.
    Kaiser, Peter
    CELL CYCLE, 2012, 11 (23) : 4414 - 4423
  • [32] Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation
    Shi, Xianghua
    Chen, Sansan
    Zhang, Yongjun
    Xie, Weiwei
    Hu, Zhiming
    Li, Hongwei
    Li, Jinlong
    Zhou, Zhongxin
    Tan, Wanlong
    ONCOTARGETS AND THERAPY, 2019, 12 : 4403 - 4413
  • [33] miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression
    Sun, Ting-Yi
    Xie, Hong-Jian
    He, Hui
    Li, Zhen
    Kong, Ling-Fei
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (02): : 1037 - 1046
  • [34] The role of exosomal CDC6 in the hirudin-mediated suppression of the malignant phenotype of bladder cancer cells
    Shen, Yang
    Ye, Hesong
    Zhang, Dongjian
    Yang, Ming
    Ji, Yuanyuan
    Tang, Longlong
    Zhu, Xudong
    Yuan, Lin
    GENE, 2022, 821
  • [35] Centrosome dysfunction contributes to chromosome instability, chromoanagenesis, and genome reprogra in cancer
    Pihan, German A.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [36] Centrosome abnormalities in squamous intraepithelial lesions (SIL) of the uterine cervix correlate with chromosome instability (CIN).
    Liang, S
    Doxsey, S
    Pihan, G
    MODERN PATHOLOGY, 2001, 14 (01) : 211A - 211A
  • [37] Centrosome abnormalities in squamous intraepithelial lesions (SIL) of the uterine cervix correlate with chromosome instability (CIN).
    Liang, S
    Doxsey, S
    Pihan, G
    LABORATORY INVESTIGATION, 2001, 81 (01) : 211A - 211A
  • [38] Activation of Cdc6 by MyoD is associated with the expansion of quiescent myogenic satellite cells
    Zhang, Keman
    Sha, Jingfeng
    Harter, Marian L.
    JOURNAL OF CELL BIOLOGY, 2010, 188 (01): : 39 - 48
  • [39] Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation
    Lim, Nicholas
    Townsend, Paul A.
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (06) : 1528 - 1534
  • [40] The Effect of High CDC6 Levels on Predicting Poor Prognosis in Colorectal Cancer
    Yang, Cheng
    Xie, Na
    Luo, Zhifei
    Ruan, Xiling
    Zhang, Yixin
    Wang, Weijiang
    Huang, Yousheng
    CHEMOTHERAPY, 2022, 67 (01) : 47 - 56